MA29816B1 - Composes de benzimidazole thiophene - Google Patents

Composes de benzimidazole thiophene

Info

Publication number
MA29816B1
MA29816B1 MA30794A MA30794A MA29816B1 MA 29816 B1 MA29816 B1 MA 29816B1 MA 30794 A MA30794 A MA 30794A MA 30794 A MA30794 A MA 30794A MA 29816 B1 MA29816 B1 MA 29816B1
Authority
MA
Morocco
Prior art keywords
thiophene compounds
compounds
benzimidazole thiophene
benzimidazole
preparing
Prior art date
Application number
MA30794A
Other languages
English (en)
Inventor
Mui Cheung
Kyle Allen Emmitte
James Michael Salovich
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA29816B1 publication Critical patent/MA29816B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE BENZIMIDAZOLE THIOPHÈNE, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS COMPOSÉS, DES PROCÉDÉS PERMETTANT DE PRÉPARER LESDITS COMPOSÉS ET L'UTILISATION LESDITS COMPOSÉS EN TANT QU'AGENTS PHARMACEUTIQUES.
MA30794A 2005-09-06 2008-03-31 Composes de benzimidazole thiophene MA29816B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71433705P 2005-09-06 2005-09-06
US78624406P 2006-03-27 2006-03-27

Publications (1)

Publication Number Publication Date
MA29816B1 true MA29816B1 (fr) 2008-09-01

Family

ID=37631488

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30794A MA29816B1 (fr) 2005-09-06 2008-03-31 Composes de benzimidazole thiophene

Country Status (29)

Country Link
US (2) US7786127B2 (fr)
EP (1) EP1937671B1 (fr)
JP (1) JP5002597B2 (fr)
KR (1) KR20080047585A (fr)
AR (1) AR055616A1 (fr)
AT (1) ATE452132T1 (fr)
AU (1) AU2006287766B2 (fr)
BR (1) BRPI0615668A2 (fr)
CA (1) CA2621879A1 (fr)
CR (1) CR9786A (fr)
CY (1) CY1109916T1 (fr)
DE (1) DE602006011192D1 (fr)
DK (1) DK1937671T3 (fr)
EA (1) EA014111B1 (fr)
ES (1) ES2337929T3 (fr)
HK (1) HK1117504A1 (fr)
HR (1) HRP20100122T1 (fr)
IL (1) IL189897A0 (fr)
JO (1) JO2578B1 (fr)
MA (1) MA29816B1 (fr)
MX (1) MX2008003173A (fr)
NO (1) NO20081160L (fr)
NZ (1) NZ566345A (fr)
PE (1) PE20070518A1 (fr)
PL (1) PL1937671T3 (fr)
PT (1) PT1937671E (fr)
SI (1) SI1937671T1 (fr)
TW (1) TW200800967A (fr)
WO (1) WO2007030361A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538305A (ja) * 2006-05-23 2009-11-05 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド
EP2032564A2 (fr) * 2006-06-02 2009-03-11 SmithKline Beecham Corporation Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique
DE602007006950D1 (de) * 2006-06-02 2010-07-15 Glaxosmithkline Llc Benzimidazol-substituierte thiophenderivate mit wirkung auf plk
US7615643B2 (en) 2006-06-02 2009-11-10 Smithkline Beecham Corporation Benzimidazole thiophene compounds
JPWO2008087736A1 (ja) * 2007-01-19 2010-05-06 宇部興産株式会社 アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
JP2010531887A (ja) * 2007-06-26 2010-09-30 グラクソスミスクライン エルエルシー ベンズイミダゾールチオフェンの調製方法
WO2009003911A1 (fr) * 2007-06-29 2009-01-08 4Sc Ag Thiophène-imidazopyridines
EP2100894A1 (fr) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
WO2009151914A1 (fr) * 2008-05-27 2009-12-17 Smithkline Beecham Corporation Procédés de traitement de néoplasmes au moyen d'une combinaison d'un inhibiteur de plk et d'un rétinoïde
WO2009154645A1 (fr) * 2008-06-20 2009-12-23 Smithkline Beecham Corporation Méthodes permettant de traiter des tumeurs du système nerveux central
SG172229A1 (en) * 2008-12-18 2011-07-28 Hoffmann La Roche Thiazolyl-benzimidazoles
WO2011049625A1 (fr) 2009-10-20 2011-04-28 Mansour Samadpour Procédé de criblage d'aflatoxine dans des produits
DK2496567T3 (en) 2009-11-05 2017-10-30 Rhizen Pharmaceuticals S A PRESENT UNKNOWN BENZOPYRANKINA MODULATORS
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
KR102574152B1 (ko) * 2020-03-27 2023-09-05 (주) 업테라 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물
KR20210122164A (ko) * 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 벤즈이미다졸 티오펜 유도체 화합물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2341409A1 (fr) 1998-08-31 2000-03-09 Merck And Co., Inc. Nouveaux inhibiteurs d'angiogenese
BR0313160A (pt) * 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
AU2003903440A0 (en) * 2003-07-04 2003-07-17 James Hardie International Finance B.V. Rainscreen apparatus and method
US7465807B2 (en) 2003-10-16 2008-12-16 Smithkline Beecham Corporation Process for preparing benzimidazole thiophenes
WO2005037627A1 (fr) 2003-10-20 2005-04-28 Nsk Ltd. Dispositif de commande
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
US20080249301A1 (en) * 2005-09-06 2008-10-09 Smithkline Beecham Corporation Regioselective Process for Preparing Benzimidazole Thiophenes
CN101331126A (zh) * 2005-09-06 2008-12-24 史密丝克莱恩比彻姆公司 作为plk调节剂的苯并咪唑噻吩化合物
US7915305B2 (en) 2006-01-23 2011-03-29 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP2032564A2 (fr) * 2006-06-02 2009-03-11 SmithKline Beecham Corporation Composés d'éther benzylique de benzimidazole thiophène substitué non cyclique
DE602007006950D1 (de) * 2006-06-02 2010-07-15 Glaxosmithkline Llc Benzimidazol-substituierte thiophenderivate mit wirkung auf plk

Also Published As

Publication number Publication date
JO2578B1 (en) 2011-02-27
EA200800546A1 (ru) 2008-08-29
AU2006287766B2 (en) 2010-06-24
WO2007030361A3 (fr) 2007-05-31
CA2621879A1 (fr) 2007-03-15
JP2009508816A (ja) 2009-03-05
BRPI0615668A2 (pt) 2011-05-24
PL1937671T3 (pl) 2010-05-31
KR20080047585A (ko) 2008-05-29
HRP20100122T1 (hr) 2010-05-31
EA014111B1 (ru) 2010-10-29
ES2337929T3 (es) 2010-04-30
CY1109916T1 (el) 2014-09-10
TW200800967A (en) 2008-01-01
HK1117504A1 (en) 2009-01-16
MX2008003173A (es) 2008-03-18
US20080214567A1 (en) 2008-09-04
WO2007030361A2 (fr) 2007-03-15
AR055616A1 (es) 2007-08-29
NO20081160L (no) 2008-05-29
AU2006287766A1 (en) 2007-03-15
CR9786A (es) 2008-05-22
PT1937671E (pt) 2010-03-12
EP1937671B1 (fr) 2009-12-16
NZ566345A (en) 2010-04-30
DE602006011192D1 (de) 2010-01-28
IL189897A0 (en) 2008-08-07
US7786127B2 (en) 2010-08-31
EP1937671A2 (fr) 2008-07-02
PE20070518A1 (es) 2007-06-12
US7595330B2 (en) 2009-09-29
DK1937671T3 (da) 2010-04-26
JP5002597B2 (ja) 2012-08-15
ATE452132T1 (de) 2010-01-15
US20070270437A1 (en) 2007-11-22
SI1937671T1 (sl) 2010-04-30

Similar Documents

Publication Publication Date Title
MA29816B1 (fr) Composes de benzimidazole thiophene
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
NO20083153L (no) Kjemiske forbindelser
MA30765B1 (fr) Derives innovants du thiophene
WO2009137391A3 (fr) Composés de benzène sulfonamide thiazole et oxazole
MA30042B1 (fr) Composes calcilytiques
ATE517883T1 (de) Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
MA31907B1 (fr) Nouveaux herbicides
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
ATE447568T1 (de) Neue pyrinderivate
MA31898B1 (fr) Compositions pharmaceutiques
WO2007016352A3 (fr) Compositions orales liquides de losartan
MA30331B1 (fr) ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION
BRPI0608287A2 (pt) agente endoparasiticida
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
WO2009102707A3 (fr) Oxazaphosphorines substituées
UA87903C2 (en) Herbicidal composition
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.